You are neglecting the value of trofinetide, and the value of...

You are neglecting the value of trofinetide, and the value of other indications outside PMS in this calc. The assertion is that value of 2591 should be $10B in 4 years time post approval for PMS (but you are only talking about PMS). You are not even doing a 'fair' comparison since PMS is approx 3 times as prevalent in populations as Freidrich's Ataxia (NEU says PMS is 1 in 8,000 to 1 in 15,000 vs FA which is 1 in 40,000). Given the market size is ~3x, you'd expect something closer to 3x the value for PMS alone.

If you had the continued development of other indications (and it is unlikely to be just 3 or 4 at that stage) and the growing income from trof both NA and ROW, you would expect a MC quite a way beyond the $10B being quoted as relevant in 4 yrs time.

I don't really understand people saying they'd be disappointed having a 5 bagger in 4 years either. Sure, everyone wants to get paid $100 per share tomorrow, but on the other hand if you know of a high conviction 400%+ in 4 years, surely you would take that every day of the week. I know I would. I know I am happy to. And I think given market size of our current indications and 'platform nature' of 2591, 1000% is actually more likely than 400%.